IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-powered antibody discovery and development company, has scheduled its third quarter fiscal year 2025 financial results announcement and business update for March 13, 2025. The company will release its financial results via press release followed by a conference call and webcast at 10:30 AM ET.
The earnings call will include a management presentation and a Q&A session. Participants can join through various channels including USA/International toll line (+1-646-307-1963) or toll-free numbers (800-715-9871 for USA and Canada) using Conference ID 3224490. A webcast will be available through the company's IR events page.
ImmunoPrecise Antibodies (NASDAQ: IPA), un'azienda di scoperta e sviluppo di anticorpi alimentata dall'IA, ha programmato l'annuncio dei risultati finanziari e un aggiornamento aziendale per il 13 marzo 2025. L'azienda pubblicherà i risultati finanziari tramite un comunicato stampa, seguito da una conferenza telefonica e un webcast alle 10:30 AM ET.
La chiamata sugli utili includerà una presentazione della direzione e una sessione di domande e risposte. I partecipanti possono unirsi tramite vari canali, inclusa la linea internazionale (+1-646-307-1963) o numeri verdi (800-715-9871 per USA e Canada) utilizzando l'ID conferenza 3224490. Un webcast sarà disponibile attraverso la pagina degli eventi IR dell'azienda.
ImmunoPrecise Antibodies (NASDAQ: IPA), una empresa de descubrimiento y desarrollo de anticuerpos impulsada por IA, ha programado el anuncio de sus resultados financieros y una actualización empresarial para el 13 de marzo de 2025. La empresa publicará sus resultados financieros a través de un comunicado de prensa, seguido de una llamada y un webcast a las 10:30 AM ET.
La llamada de ganancias incluirá una presentación de la gestión y una sesión de preguntas y respuestas. Los participantes pueden unirse a través de varios canales, incluida la línea internacional (+1-646-307-1963) o números gratuitos (800-715-9871 para EE. UU. y Canadá) utilizando el ID de conferencia 3224490. Un webcast estará disponible a través de la página de eventos IR de la empresa.
ImmunoPrecise Antibodies (NASDAQ: IPA), 인공지능 기반의 항체 발견 및 개발 회사,는 2025 회계연도 3분기 재무 결과 발표 및 사업 업데이트를 2025년 3월 13일로 예정했습니다. 회사는 오전 10시 30분 ET에 보도 자료를 통해 재무 결과를 발표한 후, 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
실적 발표 콜에는 경영진 발표와 Q&A 세션이 포함됩니다. 참가자는 국제 전화 (+1-646-307-1963) 또는 무료 전화 번호 (미국 및 캐나다의 경우 800-715-9871)를 통해 회의 ID 3224490을 사용하여 참여할 수 있습니다. 웹캐스트는 회사의 IR 이벤트 페이지를 통해 제공될 예정입니다.
ImmunoPrecise Antibodies (NASDAQ: IPA), une entreprise de découverte et de développement d'anticorps alimentée par l'IA, a programmé l'annonce de ses résultats financiers et une mise à jour commerciale pour le 13 mars 2025. L'entreprise publiera ses résultats financiers par le biais d'un communiqué de presse, suivi d'une conférence téléphonique et d'un webcast à 10h30 ET.
La conférence sur les résultats comprendra une présentation de la direction et une session de questions-réponses. Les participants peuvent se joindre par divers canaux, y compris la ligne internationale (+1-646-307-1963) ou des numéros sans frais (800-715-9871 pour les États-Unis et le Canada) en utilisant l'ID de conférence 3224490. Un webcast sera disponible via la page des événements IR de l'entreprise.
ImmunoPrecise Antibodies (NASDAQ: IPA), ein KI-gestütztes Unternehmen zur Entdeckung und Entwicklung von Antikörpern, hat die Bekanntgabe seiner dritten Quartalsfinanzergebnisse für das Geschäftsjahr 2025 sowie ein Unternehmensupdate für den 13. März 2025 geplant. Das Unternehmen wird seine Finanzergebnisse über eine Pressemitteilung veröffentlichen, gefolgt von einem Konferenzgespräch und einem Webcast um 10:30 Uhr ET.
Der Gewinnaufruf wird eine Präsentation des Managements und eine Q&A-Session umfassen. Teilnehmer können über verschiedene Kanäle teilnehmen, einschließlich der internationalen Telefonleitung (+1-646-307-1963) oder gebührenfreier Nummern (800-715-9871 für die USA und Kanada) unter Verwendung der Konferenz-ID 3224490. Ein Webcast wird über die IR-Veranstaltungsseite des Unternehmens verfügbar sein.
- None.
- None.
The Company to host an earnings conference call via webcast
Conference Call and Webcast Details
The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Thursday, March 13, 2025, at 10:30AM ET.
The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx.
***Participant Dial-In Details***
Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 3224490 or Conference Name.
***Webcast Details***
Attendee URL:
https://events.q4inc.com/attendee/849565157
Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305527448/en/
Investor Relations
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
When will ImmunoPrecise Antibodies (IPA) release its Q3 2025 earnings?
How can investors join IPA's Q3 2025 earnings call?
Where can I find IPA's historical financial reports?
What will be covered in IPA's Q3 2025 earnings call?
